World's Best Scientists 2026 revealed!
Axel Hauschild

Axel Hauschild

D-Index & Metrics

Medicine

D-Index
119
Citations
81537
World Ranking
3809
National Ranking
209

Overview

Axel Hauschild is affiliated with Kiel University in Germany and has a significant publication record primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their research focuses heavily on oncology, molecular biology, epidemiology, immunology, and dermatology.

Their work centers around various key topics including:

  • Cutaneous Melanoma Detection and Management
  • Nonmelanoma Skin Cancer Studies
  • Melanoma and MAPK Pathways
  • CAR-T Cell Therapy Research
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Hedgehog Signaling Pathway Studies

Hauschild's most frequent publication venues include:

  • European Journal of Cancer
  • Journal of Clinical Oncology
  • JDDG Journal der Deutschen Dermatologischen Gesellschaft
  • Annals of Oncology
  • SKIN The Journal of Cutaneous Medicine

Notable recent papers by Hauschild include:

  • Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial, 2020, The Lancet Oncology
  • Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma, 2020, New England Journal of Medicine
  • Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial, 2021, The Lancet Oncology
  • European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment, 2020, European Journal of Cancer
  • European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022, 2022, European Journal of Cancer

In collaboration, Hauschild has frequently worked with the following coauthors:

  • Dirk Schadendorf
  • Claus Garbe
  • Reinhard Dummer
  • Friedegund Meier
  • Caroline Robert

Overall, Axel Hauschild's research activities are positioned at the intersection of clinical oncology and molecular biology with a strong emphasis on melanoma and skin cancer, involving therapeutic strategies and immune response mechanisms. Their scholarly contributions gain visibility through multiple articles in well-established oncology and dermatology journals, supporting ongoing developments in cancer treatment and diagnostics.

Best Publications

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

    Axel Hauschild;Jean Jacques Grob;Lev V. Demidov;Thomas Jouary

  • Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Caroline Robert;Boguslawa Karaszewska;Jacob Schachter;Piotr Rutkowski

  • Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    G.V. Long;D. Stroyakovskiy;H. Gogas;E. Levchenko

  • Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

    Jeffrey S. Weber;Katharina C. Kähler;Axel Hauschild

  • Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

    Aleksandar Sekulic;Michael R. Migden;Anthony E. Oro;Luc Dirix

  • Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Georgina V. Long;Georgina V. Long;Daniil Stroyakovskiy;Helen Gogas;Evgeny Levchenko

  • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma

    G. V. Long;A. Hauschild;M. Santinami;V. Atkinson

  • Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

    Alexander M M Eggermont;Vanna Chiarion-Sileni;Jean-Jacques Grob;Reinhard Dummer

  • PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma

    Michael R. Migden;Danny Rischin;Chrysalyne D. Schmults;Alexander Guminski

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

    Caroline Robert;Jean J Grob;Daniil Stroyakovskiy;Boguslawa Karaszewska

  • Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

    Georgina V. Long;Uwe Trefzer;Michael A. Davies;Richard F. Kefford

  • Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Antoni Ribas;Richard Kefford;Margaret A. Marshall;Cornelis J.A. Punt

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

    Alexander M. M. Eggermont;Stefan Suciu;Mario Santinami;Alessandro Testori

  • MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

    Paolo A. Ascierto;Dirk Schadendorf;Carola Berking;Sanjiv S. Agarwala

  • Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

    Jason Chesney;Igor Puzanov;Frances Collichio;Parminder Singh

  • Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects

    Claus Garbe;Thomas K. Eigentler;Ulrich Keilholz;Axel Hauschild

Frequent Co-Authors

Dirk Schadendorf
Dirk Schadendorf University of Duisburg-Essen
Claus Garbe
Claus Garbe University of Tübingen
Reinhard Dummer
Reinhard Dummer University of Zurich
Caroline Robert
Caroline Robert University of Paris-Saclay
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Georgina V. Long
Georgina V. Long University of Sydney
Ralf Gutzmer
Ralf Gutzmer Hannover Medical School
Jochen Utikal
Jochen Utikal German Cancer Research Center
James Larkin
James Larkin Royal Marsden NHS Foundation Trust
John M. Kirkwood
John M. Kirkwood University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying medicine in the USA isn't the only way to launch a successful career in healthcare. Many students are exploring related paths through flexible, affordable online degrees. For instance, some opt for a career in pharmacy by enrolling in pharmacy school online. This is a great choice for those interested in medications, patient care, and clinical research.

Another emerging field is health informatics. With healthcare informatics degree programs, you can play a critical role in managing medical data and supporting digital healthcare solutions.

Some students prefer administrative roles that are vital for keeping hospitals and clinics running smoothly. Medical billing and coding classes online teach you the skills required for recording, processing, and safeguarding patient information.

If your goal is advanced patient care, there are also affordable np programs available online. These programs allow nurses to build advanced clinical skills and take on leadership roles.

No matter your interests, online healthcare degrees open diverse pathways to rewarding careers in medicine and beyond.

Best Scientists Citing Axel Hauschild

Trending Scientists